Continuous glucose monitoring after liver transplant
Post-discharge Glycemic Control After Liver Transplant and Impact on Transplant Outcomes
Icahn School of Medicine at Mount Sinai · NCT07216508
This project will try a wearable continuous glucose sensor for people who had a liver transplant and showed high blood sugar in the hospital to see how glucose behaves after they go home.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Icahn School of Medicine at Mount Sinai (other) |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT07216508 on ClinicalTrials.gov |
What this trial studies
This observational study enrolls liver transplant recipients who had an inpatient glucose reading above 180 mg/dL. Participants will wear a blinded Libre 3+ glucose sensor after hospital discharge for up to 30 days, with data shared retrospectively with participants and their providers. Participants will be invited to wear another blinded sensor at 6 and 12 months to track longer-term patterns. Researchers will describe CGM-based glycemic metrics after discharge and examine relationships between those metrics and clinical transplant outcomes.
Who should consider this trial
Good fit: Ideal candidates are liver transplant recipients discharged to home who had an inpatient glucose >180 mg/dL and did not receive a simultaneous kidney or pancreas transplant.
Not a fit: Patients discharged to a rehabilitation or nursing facility, those with contraindications to sensor placement, or those with combined kidney or pancreas transplants are unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, this approach could identify post-discharge hyperglycemia patterns that help clinicians target interventions and reduce transplant-related complications.
How similar studies have performed: Continuous glucose monitoring has provided useful glycemic data in diabetes and some transplant settings, but its routine use specifically after liver transplant is still limited and under study.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: • inpatient liver transplant participants who have had an inpatient glucose greater than 180mg/dL Exclusion Criteria: * having a planned discharge to a rehabilitation or nursing facility, * a contraindication to sensor placement, * if discharge is anticipated to be \>30 days post-transplant, or * if recent transplant also included a kidney or pancreas transplant
Where this trial is running
New York, New York
- Mount Sinai Hospital — New York, New York, United States (RECRUITING)
Study contacts
- Principal investigator: Grenye O'Malley, MD — Icahn School of Medicine at Mount Sinai
- Study coordinator: Grenye O'Malley
- Email: grenye.o'malley@mssm.edu
- Phone: 212-241-7173
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Liver Transplant, Post Transplant Diabetes, Type 2 Diabetes, liver transplant, hyperglycemia, diabetes, continuous glucose monitoring, glucose sensor